Skip to main navigation

Skip to Content

Overview
Stock Information
SEC Filings
Corporate Governance
Company
Contact Us
ImmunityBio.com

Press Releases

Press Releases

Year

ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG

Feb 05, 2024

ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million

Jan 02, 2024

Pagination

First page
Previous page
Page 1
Page 2
Current page 3

Displaying 21 - 22 of 22

IR Tools

© 2024 ImmunityBio, Inc. All Rights Reserved.

A member of the NantWorks ecosystem of companies

'ImmunityBio', 'ImmunityBio Care', 'Anktiva', 'ThAnktiva', 'haNK', 'taNK', 'ceNK', 'NK-92', 'Nant Cancer Vaccine', 'NANT 001', 'NANT XL', 'NANT 001 and Design', 'QUILT', 'Outsmart Your Disease', 'Smart Therapies for Difficult Diseases', 'Nantkwest', 'VivaBioCell', and 'Infacell' are trademarks or registered trademarks of ImmunityBio, Inc., its subsidiaries and affiliates.

The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.

The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.

The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.

NantKwest

Visit ImmunityBio.com

Social icons